WallStSmart

Cross Country Healthcare Inc (CCRN)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 6464% more annual revenue ($65.77B vs $1.00B). MRK leads profitability with a 13.6% profit margin vs -9.8%. MRK appears more attractively valued with a PEG of 5.36. MRK earns a higher WallStSmart Score of 50/100 (D+).

CCRN

Hold

36

out of 100

Grade: F

Growth: 2.0Profit: 2.0Value: 5.7Quality: 9.0
Piotroski: 4/9Altman Z: 4.82

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.30
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CCRNUndervalued (+39.9%)

Margin of Safety

+39.9%

Fair Value

$13.76

Current Price

$13.18

$0.58 discount

UndervaluedFair: $13.76Overvalued
MRKSignificantly Overvalued (-49.3%)

Margin of Safety

-49.3%

Fair Value

$80.88

Current Price

$120.79

$39.91 premium

UndervaluedFair: $80.88Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CCRN3 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
4.8210/10

Safe zone — low bankruptcy risk

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$285.64B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

Areas to Watch

CCRN4 concerns · Avg: 2.3/10
Market CapQuality
$407.14M3/10

Smaller company, higher risk/reward

PEG RatioValuation
11.462/10

Expensive relative to growth rate

Return on EquityProfitability
-31.5%2/10

ROE of -31.5% — below average capital efficiency

Revenue GrowthGrowth
-17.8%2/10

Revenue declined 17.8%

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : CCRN

The strongest argument for CCRN centers on Price/Book, Debt/Equity, Altman Z-Score.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : CCRN

The primary concerns for CCRN are Market Cap, PEG Ratio, Return on Equity.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Key Dynamics to Monitor

CCRN profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.

CCRN carries more volatility with a beta of 0.36 — expect wider price swings.

MRK is growing revenue faster at 4.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 36/100). CCRN offers better value entry with a 39.9% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cross Country Healthcare Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Cross Country Healthcare, Inc. provides talent management and other consulting services for healthcare clients in the United States. The company is headquartered in Boca Raton, Florida.

Visit Website →

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?